LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 12 of 497
Next
>>
>
276 to 300 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	Seliciclib	0.04	uM	LJP5	3	J06	72	hr	1657	5764	5505	1.0469	1.0671
BT-20	Ruxolitinib	0.04	uM	LJP5	1	O18	72	hr	1657	5046	5505	0.9165	0.8805
BT-20	Ruxolitinib	0.04	uM	LJP5	2	O18	72	hr	1657	5411	5505	0.9828	0.9754
BT-20	Ruxolitinib	0.04	uM	LJP5	3	O18	72	hr	1657	5130	5505	0.9318	0.9024
BT-20	XL147	0.04	uM	LJP5	1	G12	72	hr	1657	5908	5505	1.0731	1.1046
BT-20	XL147	0.04	uM	LJP5	2	G12	72	hr	1657	5828	5505	1.0585	1.0838
BT-20	XL147	0.04	uM	LJP5	3	G12	72	hr	1657	5720	5505	1.0389	1.0557
BT-20	Saracatinib	0.04	uM	LJP6	1	D12	72	hr	1657	5549	5505	1.0079	1.0113
BT-20	Saracatinib	0.04	uM	LJP6	2	D12	72	hr	1657	5361	5505	0.9737	0.9624
BT-20	Saracatinib	0.04	uM	LJP6	3	D12	72	hr	1657	6035	5505	1.0961	1.1376
BT-20	Selumetinib	0.04	uM	LJP6	1	M12	72	hr	1657	5774	5505	1.0487	1.0697
BT-20	Selumetinib	0.04	uM	LJP6	2	M12	72	hr	1657	6445	5505	1.1706	1.2441
BT-20	Selumetinib	0.04	uM	LJP6	3	M12	72	hr	1657	6159	5505	1.1187	1.1698
BT-20	Sirolimus	0.04	uM	LJP6	1	L18	72	hr	1657	3582	5505	0.6506	0.5001
BT-20	Sirolimus	0.04	uM	LJP6	2	L18	72	hr	1657	3506	5505	0.6368	0.4803
BT-20	Sirolimus	0.04	uM	LJP6	3	L18	72	hr	1657	3489	5505	0.6337	0.4759
BT-20	Sorafenib	0.04	uM	LJP6	1	B12	72	hr	1657	5124	5505	0.9307	0.9008
BT-20	Sorafenib	0.04	uM	LJP6	2	B12	72	hr	1657	4581	5505	0.8321	0.7597
BT-20	Sorafenib	0.04	uM	LJP6	3	B12	72	hr	1657	5663	5505	1.0286	1.0409
BT-20	SU11274	0.04	uM	LJP5	1	J12	72	hr	1657	5572	5505	1.0120	1.0172
BT-20	SU11274	0.04	uM	LJP5	2	J12	72	hr	1657	5838	5505	1.0604	1.0864
BT-20	SU11274	0.04	uM	LJP5	3	J12	72	hr	1657	5648	5505	1.0259	1.0370
BT-20	Fedratinib	0.04	uM	LJP5	1	L06	72	hr	1657	5674	5505	1.0306	1.0437
BT-20	Fedratinib	0.04	uM	LJP5	2	L06	72	hr	1657	6014	5505	1.0923	1.1321
BT-20	Fedratinib	0.04	uM	LJP5	3	L06	72	hr	1657	5362	5505	0.9739	0.9627

|<
<<
Previous
Page 12 of 497
Next
>>
>
276 to 300 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)